FGFR-IN-9 

FGFR-IN-9 (Compound 19) is a potent, reversible and orally active FGFR inhibitor with an IC₅₀ of 17.1, 29.6, 30.7, 46.7 and 64.3 nM against FGFR4^WT, FGFR3, FGFR4^V550L, FGFR2 and FGFR1, respectively^[1].

FGFR-IN-9 (Compound 19) (0-2 mM; 72 h) inhibits HUH7 cells with an IC₅₀ of 94.7 ± 28.6 nM, and inhibits proliferation with IC₅₀s of 82.5 ± 19.2 nM and 260.0 ± 50.2 nM against Ba/F3 FGFR4^WT and Ba/F3 FGFR4^V550L cells, respectively^[1].
FGFR-IN-9 (0-400 nM; 4 h) inhibits FGFR signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

FGFR-IN-9 (Compound 19) (30 and 45 mg/kg; i.g.; daily for 3 weeks) shows antitumor activity in the HUH7 xenograft mouse model^[1].
In Vivo Pharmacokinetic Profile Data for FGFR-IN-9 (Compound 19) ^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

492.59

C₂₅H₂₈N₆O₃S

3024090-08-9

O=S(N1C=CC2=CN=C(NC3=CC=C(N4C[C@H](C)N[C@H](C)C4)C=C3)N=C21)(C5=CC=CC(OC)=C5)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xie W, et al. Discovery of 2-Amino-7-sulfonyl-7 H-pyrrolo [2, 3-d] pyrimidine Derivatives as Potent Reversible FGFR Inhibitors with Gatekeeper Mutation Tolerance: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2022.